Esperion's (ESPR) first-quarter earnings and sales beat estimates on the back of better-than-expected collaboration revenues.
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q1 2024 Earnings Call Transcript May 7, 2024 Esperion Therapeutics, Inc. beats earnings expectations. Reported EPS is $0.00032, expectations were $-0.17. ESPR isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Ladies and gentlemen, thank you for […]
Discover how Esperion Therapeutics achieved a historic revenue milestone and expanded market potential in its first quarter of 2024.